Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on Analytical Methods of Irbesartan and its Combinations in Pharmaceutical Dosage Forms

Author(s): Calamur Nagarajan Nalini* and Nivedhitha Mathivanan

Volume 16, Issue 8, 2020

Page: [1020 - 1029] Pages: 10

DOI: 10.2174/1573412915666190802164428

Price: $65

Abstract

Pharmaceutical analysis plays an indispensable role in various stages of drug pipeline including drug development, fabrication of formulation, stability studies and quality control. It is also used for characterizing the composition of different dosage forms in quantitative and qualitative ways. Comprehensive literature survey forms the foundation stone for the focused analysis of research activity. Irbesartan is a hypertension antagonist chiefly employed in the treatment of high blood pressure which is an Angiotensin II Receptor blocker. The multiple mixtures of various antihypertensive medicaments raise challenges in the method development and validation. A genuine venture is undertaken to compile the literatures related to the antihypertensive drug Irbesartan published in various peer reviewed journals. HPLC and UV spectrophotometry are the most preferred analytical techniques when compared to other methods. This present review provides an in-depth assortment of various analytical techniques published for Irbesartan and its combinations, which will help the researchers in their future endeavors.

Keywords: Analytical methods, irbesartan, antihypertensive, amlodipine, hydrochlorothiazide, pharmaceutical dosage.

Next »
Graphical Abstract

[1]
Rahman, N.; Azmi, S.N.; Wu, H.F. The importance of impuri-ty analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11, 69-74.
[http://dx.doi.org/10.1007/s00769-006-0095-y]
[2]
Zeid, A. Alothman.; Nafisur Rahman. Analytical techniques in pharmaceutical analysis:A review. Arab. J. Chem., 2017, 10, S1409-S1421.
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[3]
Ana, C. Kogawa; Hérida, R.N. Salgado. Impurities and forced degradation studies: A review. Curr. Pharm. Anal., 2016, 12, 18-24.
[4]
Jain, D.; Basniwal, P.K. Forced degradation and impurity profiling: recent trends in analytical perspectives. J. Pharm. Biomed. Anal., 2013, 86, 11-35.
[http://dx.doi.org/10.1016/j.jpba.2013.07.013] [PMID: 23969330]
[5]
Zeid, A.A.; Nafisur, R.; Raza, M.S. Review on Pharmaceutical impurities, stability studies and degradation products: An Analytical Approach. Revi. Adv. Sci. Engi., 2013, 2(2), 155-166.
[6]
Burnier, M.; Brunner, H.R. Angiotensin II receptor antagonists. Lancet, 2000, 355(9204), 637-645.
[http://dx.doi.org/10.1016/S0140-6736(99)10365-9] [PMID: 10696996]
[7]
Marino, M.R.; Langenbacher, K.; Ford, N.F.; Uderman, H.D. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J. Clin. Pharmacol., 1998, 38(3), 246-255.
[http://dx.doi.org/10.1002/j.1552-4604.1998.tb04422.x] [PMID: 9549663]
[8]
Aronow, W.S. Treatment of systemic hypertension. Am. J. Cardiovasc. Dis., 2012, 2(3), 160-170.
[PMID: 22937486]
[9]
Massie, B.M.; Carson, P.E.; McMurray, J.J.; Komajda, M.; McKelvie, R.; Zile, M.R.; Anderson, S.; Donovan, M.; Iverson, E.; Staiger, C.; Ptaszynska, A. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med., 2008, 359(23), 2456-2467.
[http://dx.doi.org/10.1056/NEJMoa0805450] [PMID: 19001508]
[10]
Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I. Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345(12), 851-860.
[http://dx.doi.org/10.1056/NEJMoa011303] [PMID: 11565517]
[11]
Borghi, C.; Cicero, A.F. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review. High Blood Press. Cardiovasc. Prev., 2012, 19(1), 19-31.
[http://dx.doi.org/10.2165/11632100-000000000-00000] [PMID: 22670584]
[12]
Forni, V.; Wuerzner, G.; Pruijm, M.; Burnier, M. Long-term use and tolerability of irbesartan for control of hypertension. Integr. Blood Press. Control, 2011, 4, 17-26.
[PMID: 21949635]
[13]
https: //www.fda.gov/ NewsEvents/ Newsroom/FDA
[14]
Sabir, M.A.; Moloy, M.; Bhasin, P.S. HPLC method development and validation: A review. Int. Res. J. Pharm., 2013, 4(4), 39-46.
[15]
Al-Momani, I.F. Determination of hydrochlorothiazide and enalapril maleate in tablet formulations by reversed-phase HPLC. Turk. J. Chem., 2001, 25, 49-54.
[16]
Attimarad, M.; Ahmed, K.K.; Aldhubaib, B.E.; Harsha, S. High-performance thin layer chromatography: A powerful analytical technique in pharmaceutical drug discovery. Pharm. Methods, 2011, 2(2), 71-75.
[http://dx.doi.org/10.4103/2229-4708.84436] [PMID: 23781433]
[17]
Bilek, M. namieśnik, j. Chromatographic techniques in phar-maceutical analysis in poland: history and the presence on the basis of papers published in selected polish pharmaceutical journals in xx century. Acta Pol. Pharm., 2016, 73(3), 605-612.
[PMID: 27476277]
[18]
Rao, P.K.; Rao, M.C. Spectrophotometric methods in the analysis of drugs in pure and dosage forms. Int. J. Chem. Sci., 2016, 14(4), 2389-2396.
[19]
Soni, P.; Sinha, D.; Patel, R. Simple, Rapid and sensitive UV-Visible spectrophotometric method for determination of antidepressant amitriptyline in pharmaceutical dosage forms. J. Spectro. 2013, 5.
[20]
Nevídalová, H.; Michalcová, L.; Glatz, Z. Capillary electrophoresis-based approaches for the study of affinity interactions combined with various sensitive and nontraditional detection techniques. Electrophoresis, 2019, 40(5), 625-642.
[http://dx.doi.org/10.1002/elps.201800367] [PMID: 30600537]
[21]
Özkan, S.A.; Uslu, B.; Aboul-Enei, H.Y. Analysis of pharmaceuticals and biological fluids using modern electroanalytical techniques. Crit. Rev. Anal. Chem., 2003, 33(3), 155-181.
[http://dx.doi.org/10.1080/713609162]
[22]
Hisham, E.A. El-Henawee. M.E.; ELSaved, H.M.; Ayad, M.M. Spectrophotometric and spectro-fluorimetric methods for analysis of Tramadol, Acebutol and Dothiepin in pharmaceutical preparations. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2006, 65(5), 1087-1092.
[http://dx.doi.org/10.1016/j.saa.2006.02.008] [PMID: 16716651]
[23]
Chauhan, A.; Bharti, M. Chauha,n P. Analytical Method Development and Validation: A Concise Review. J. Anal. Bioanal. Tech., 2015, 6, 233.
[24]
Banjare, L.; Chandra, J.K.; Patel, P. Method development and validation for estimation of Irbesartan in bulk drug and phar-maceutical dosage. J. Drug Deliv. Ther., 2013, 3(6), 87-90.
[http://dx.doi.org/10.22270/jddt.v3i6.708]
[25]
Kalyani, G.; Adjuad, B. Stability indicating assay and estimation of irbesartan by first order uv derivative spec-trophotometry. Ijpsr, 2017, 8(9), 3817-3821.
[26]
Anupama, B.; Kurumaddali, A.; Bhargav, S.N.; Surendra, A. UV spectrophotometric method for irbesartan. Tablet, IJRPC, 2012, 2(1), 20-21.
[27]
Nissankararao, S.; Anil Kumar, A.; Bhimavarapu, R.D.; Krishna Prasanna, V. Estimation of Irbesartan in bulk and dosage Forms by new simple UV spectrophotometry using hydrotropic technique. Pharm. Anal. Acta, 2013, 4(8), 3-4.
[http://dx.doi.org/10.4172/2153-2435.1000265]
[28]
Kumar, J.S.; Annapurna, M.M. New spectrophotometric methods for the simultaneous determination of irbesartan and hydrochlorothiazide in combined dosage forms. Pharm. Methods, 2015, 2(6), 120-125.
[http://dx.doi.org/10.5530/phm.2015.6.18]
[29]
Shakya, P. Pushpendra Kumar Jain, S. P.; Shrivastava, Asmita Gajbhiye. Simultaneous estimation of Irbesartan And Hydro-chlorothiazide by UV spectroscopy. Int. J. Pharm. Pharm. Sci., 2015, 7(6), 389-391.
[30]
Sridharan, D.; Thenmozhi, A.; Sundaranandavalli, Vr.; Pal-anikumar, B. Simultaneous estimation of Irbesartan And Hy-drochlorothiazide in combined pharmaceutical dosage form by UV spectroscopy using Multicomponent Mode of Analy-sis. Int. J. Chemtech Res., 2010, 2(2), 876-879.
[31]
Vetuschi, C.; Giannandrea, A.; Carlucci, G.; Mazzeo, P. Determination of hydrochlorothiazide and irbesartan in pharmaceuticals by fourth-order UV derivative spectrophotometry. Farmaco, 2005, 60(8), 665-670.
[http://dx.doi.org/10.1016/j.farmac.2005.04.013] [PMID: 15963513]
[32]
Mukthinuthalapati Mathrusri Annapurna.Simultaneous de-termination of irbesartan and hydrochlorothiazide by spectro-photometry. IJPT, 2016, 8(3), 17545-17553.
[33]
Divya, K.; Sruthi, V.; Sravan Kumar, G.; Sanayaima Huidrom, A.H.; Prasad, V.V. Simultaneous estimation of Irbesartan and hydrochlorothiazide in combined pharmaceutical dosage form by UV spectroscopy. Int. J. Innovative Pharmaceut. Sci. Res., 2014, 2(8), 1674-1680.
[34]
Sojitra, R.; Raj, H.; Jain, V. Development and validation of analytical method for Irbesartan and atrovastatin by simultaneous equation spectroscopic method. Int. J. Adv. Scientific Res., 2015, 1(4), 194-198.
[35]
Virani, P.; Sojitra, R.; Savaj, B.; Jain, V.H. Simultaneous estimation of Irbesartan And Atorvastatin by Q absorption ratio method in their synthetic mixture use in cardiac condition. Innovare. J. Educ., 2015, 3(1), 20-24.
[36]
Patel, K.; Darji, V.; Rakshit, S.; Patel, S.A. Simultaneous spec-trophotometric estimation of irbesartan and hydrochlorothia-zine in tablets. Int. Res. J. Pharm., 2011, 2(3), 202-207.
[37]
Ramzia, I. El-Bagary.; Hanaa, M.; Hashem.; Waleed, A.; Ebeid. Farouk, M.; EL-Aziz, OA.; Hemdanb. Spectrofluori-metric, spectrophotometric and LC determination of Irbesar-tan J. Chem. Pharm. Res., 2011, 3(4), 722-733.
[38]
El-Sutohy, MM.; El-Shaboury, SR.; Hussein, SA.; Mohamed, NA. Validated Non-Extractive spectrophotometric methods for de-termination of some Angiotensin II Receptor Antagonists Asian. J. Pharm. Anal., 2013, 3(1), 3-8.
[39]
Rahman, N.; Siddiqui, M.R.; Azmi, S.N. Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry. Chem. Pharm. Bull. (Tokyo), 2006, 54(5), 626-631.
[http://dx.doi.org/10.1248/cpb.54.626] [PMID: 16651756]
[40]
Joseph-Charles, J.; Brault, S.; Boyer, C.; Langlois, M.H.; Cabrero, L.; Dubost, J.P. Simultaneous determination of irbesartan and hydrochlorothiazide in tablets by derivative spectrophotometry. Anal. Lett., 2003, 36(11), 2485-2495.
[http://dx.doi.org/10.1081/AL-120024337]
[41]
Albero, I.; Ródenas, V.; García, S.; Sánchez-Pedreño, C. Determination of irbesartan in the presence of hydrochlorothiazide by derivative spectrophotometry. J. Pharm. Biomed. Anal., 2002, 29(1-2), 299-305.
[http://dx.doi.org/10.1016/S0731-7085(02)00073-0] [PMID: 12062690]
[42]
Erk, N. Three new spectrophotometric methods applied to the simultaneous determination of hydrochlorothiazide and irbesartan. Pharmazie, 2003, 58(8), 543-548.
[PMID: 12967029]
[43]
Abdellatef, H.E. Extractive-spectrophotometric determination of disopyramide and irbesartan in their pharmaceutical formulation. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2007, 66(4-5), 1248-1254.
[http://dx.doi.org/10.1016/j.saa.2006.06.015] [PMID: 16920393]
[44]
Asati, A.; Shinde, A.; Malik, S. Quantitative analysis method development and validation for irbesartan in bulk drug by ul-traviolet spectroscopy. J. Adv. Pharm. Edu., 2014, 4, 101-104.
[45]
Pradhan, K.; Mishra, U.S.; Pattnaik, S. Method development, validation and stability study of irbesartan in bulk and phar-maceutical dosage form by UV-spectrophotometric method. Int J. Pharm. Biol. Sci. Arch., 2011, 2, 1114-1122.
[46]
Tulja Rani, G.; Gowri Sankar, D.; Madhavi, L.; Satyanaraya-na, B. Extractive visible spectrophotometric method for de-termination of telmisartan and irbesartan in bulk and pharma-ceutical formulations. Asian. J. Pharm. Clin. Res., 2012, 5, 41-44.
[47]
Shehata, M. Simple novel spectrophotometric and spectroflu-orimetric methods for determination of some antihypertensive Drugs. J. Am. Sci., 2011, 7, 300-312.
[48]
Omar, M.A.; Abdelmageed, O.H.; Abdel-Gaber, A.A.; Abdel-Megied, A.M. Spectrophotometric and spectrofluorimetric de-termination of certain angiotensin receptor blockers through complex formation. J. Pharmaceut. Sci. Res., 2011, 3(10), 1499.
[49]
Hafez, H.M.; Elshanawane, A.A.; Abdelaziz, L.M.; Kamal, M.M. Quantitative determination of three Angiotensin-II-receptor antagonists in presence of hydrochlorothiazide by RP-HPLC in their tablet preparations, Iranian journal of pharmaceutical research. Iran. J. Pharm. Res., 2013, 12(4), 635-643.
[PMID: 24523743]
[50]
Swamy, G.S.; Kumar, J.; Rao, S. A validated reverse phase HPLC method for the simultaneous estimation of irbesartan and amlodipine in pharmaceutical dosage form. World J. Pharm. Pharm. Sci., 2014, 3, 996-1007.
[51]
Milind, B.; Ubale Vitthal, D. DhakaneVilas, D., Chaudhari, R. Simultaneous. high perfor-mance liquid chromatographic determination of irbesartan and hydrochlorothiazide in pharmaceutical dosage form. JPSI. 2012, 25-28.
[52]
Alanazi, A.M.; Abdelhameed, A.S.; Khalil, N.Y.; Khan, A.A.; Darwish, I.A. HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets. Acta Pharm., 2014, 64(2), 187-198.
[http://dx.doi.org/10.2478/acph-2014-0014] [PMID: 24914719]
[53]
Hemamrutha, S.; Rambabu, R.; Vidhyadhara, S. Development And Validation of RP-HPLC method for simultaneous estima-tion of irbesartan and hydrochlorothiazide in bulk and phar-maceutical dosage Forms. Int. J. Pharm., 2013, 3(2), 360-363.
[PMID: 23545397]
[54]
Chabukswar, A.R.; Jagdale, S.C.; Kuchekar, B.S.; Lokhande, P.D.; Shinde, S.N.; Ingale, K.D.; Kolsure, A.K. Development and validation of a RP-HPLC-PDA method for simultaneous estimation of hydrochlorothiazide and irbesartan. Pharma Chem., 2010, 2(4), 148-154.
[55]
Bhukya, R. Elizabeth, Y.; Dhanalaxmi, K.; Nagarjuna Red-dy,D. Method Development And Validation Of irbesartan and hydrochlorthiazide by RP-HPLC in bulk and pharmaceutical dosage form. Int. J. Pharm., 2013, 3(3), 521-526.
[56]
Nagamani, M.; Sahoo, S.K.; Kavitha, D.; Ch, B.; Mahapatra, L. Validated RP-HPLC method for simultaneous estimation of irbesartan and hydrochlorothiazide in tablet dosage form. Int.J. Pharma Res. Health Sci., 2017, 5(5), 1419-1423.
[57]
Ravisankar, P.; Devi, M.S.; Ravali, B.; Tejaswini, K.; Balaji, D.; Babu, P.S. Rapid simultaneous separation of four sartans by isocratic RP-HPLC method: Application to determination of olmisartan in pharmaceutical dosage form. J. Chem. Pharmaceut. Sci., 2015, 8(1), 61.
[58]
Ravisankar, P.; Vineela, C.; Koushik, O.S.; Babu, P.S. Novel Simultaneous Separation and Quantitative determination of telmisartan, losartan, olmesartan and irbesartan in presence of hydrochlorothiazide by isocratic RP-HPLC. Adv. J. Pharm. Life Sci. Res., 2015, 3, 1-8.
[59]
Eswarudu, M.M.; Chary, T.N.; Junapudi, S.; Sushma, M. RP-HPLC method development and validation for simultaneous estimation of irbesartan and hydrochlorothiazide in pharma-ceutical dosage form. Asian J. Res. Chem, 2012, 5(4), 472-476.
[60]
Raja, B.; Himasri, P.; Ramadevi, B. RP-HPLC method for the simultaneous estimation of irbesartan and hydrochlorothia-zide in pharmaceutical dosage form. Int. Res. J. Pharmaceuti. Appl. Sci., 2012, 2(3), 29-38.
[61]
Raju, R.R.; Babu, N.B. Development and validation of HPLC method for the estimation of irbesartan in pharmaceutical dosage form. Pharmacophore, 2011, 2(2), 145-149.
[62]
Tahir, M.S.; Adnan, A.; Syed, Q. Chromatographic resolution of angiotensin II receptor antagonists (sartans). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2016, 1027, 57-63.
[http://dx.doi.org/10.1016/j.jchromb.2016.05.023] [PMID: 27258943]
[63]
Mhaske, R.A.; Sahasrabudhe, S. Mhaske, AA. RP-HPLC method for simultaneous determination of irbesartan, losar-tan, hydrohlorothiazide and chlorthalidone-Application To Commercially Available Drug Products. Int. J. Pharm. Sci. Res., 2012, 3(4), 1116.
[64]
Vujić, Z.; Mulavdić, N.; Smajić, M.; Brborić, J.; Stankovic, P. Simultaneous analysis of irbesartan and hydrochlorothiazide: an improved HPLC method with the aid of a chemometric protocol. Molecules, 2012, 17(3), 3461-3474.
[http://dx.doi.org/10.3390/molecules17033461] [PMID: 22426527]
[65]
Shakya, A.K.; Al-Hiari, Y.M.; Alhamami, O.M. Liquid chromatographic determination of irbesartan in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 848(2), 245-250.
[http://dx.doi.org/10.1016/j.jchromb.2006.10.044] [PMID: 17118719]
[66]
Erk, N. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 784(1), 195-201.
[http://dx.doi.org/10.1016/S1570-0232(02)00759-6] [PMID: 12504198]
[67]
Bae, S.K.; Kim, M.J.; Shim, E.J.; Cho, D.Y.; Shon, J.H.; Liu, K.H.; Kim, E.Y.; Shin, J.G. HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. Biomed. Chromatogr., 2009, 23(6), 568-572.
[http://dx.doi.org/10.1002/bmc.1154] [PMID: 19277953]
[68]
Ferreirós, N.; Iriarte, G.; Alonso, R.M.; Jiménez, R.M. Development of a solid phase extraction procedure for HPLC-DAD determination of several angiotensin II receptor antagonists in human urine using mixture design. Talanta, 2007, 73(4), 748-756.
[http://dx.doi.org/10.1016/j.talanta.2007.04.062] [PMID: 19073097]
[69]
Caudron, E.; Laurent, S.; Billaud, E.M.; Prognon, P. Simultaneous determination of the acid/base antihypertensive drugs celiprolol, bisoprolol and irbesartan in human plasma by liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2004, 801(2), 339-345.
[http://dx.doi.org/10.1016/j.jchromb.2003.11.009] [PMID: 14751804]
[70]
Mirza, A.Z. HPLC-UV method for simultaneous determina-tion of irbesartan, candesartan, gliquidone and pioglitazone in formulations and in human serum. J. Chin. Pharm. Sci., 2018, 27(4), 273-280.
[http://dx.doi.org/10.5246/jcps.2018.04.028]
[71]
Goswami, N. A validated stability-indicating liquid chromatographic method for determination of process related impurities and degradation behavior of Irbesartan in solid oral dosage. J. Adv. Pharm. Technol. Res., 2014, 5(1), 33-40.
[http://dx.doi.org/10.4103/2231-4040.126985] [PMID: 24695518]
[72]
Senthil Kumar, S.; Ritesh Kumar Srivastava, V. Srinivas Rao. Determination Of 2-Cyano-4′-Bromomethyl biphenyl geno-toxic impurity in irbesartan drug substances using HPLC technique. Int. J. Pharm. Pharm. Sci., 2016, 8(12), 225-230.
[http://dx.doi.org/10.22159/ijpps.2016v8i12.14682]
[73]
Srinivasu, T. Development of a new validated stability indicating RP-HPLC method for the determination of irbesartan and hydrochlorothiazide. Asian J. Pharm., 2018, 12(01), 333-339.
[74]
Prabhu, P.; Muralidhar, M. Development & validation of High performance liquid chromatography method for simultaneous determination of Irbesartan and its related impurities in phar-maceutical tablets. Int. J. Pharm. Sci. Drug Res., 2014, 6(2), 145-153.
[75]
Rane, V.P.; Patil, K.R.; Sangshetti, J.N.; Yeole, R.D.; Shinde, D.B. Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations. J. Chromatogr. Sci., 2010, 48(7), 595-600.
[http://dx.doi.org/10.1093/chromsci/48.7.595] [PMID: 20819286]
[76]
Soni, C. Patel Dr, C.J.; Patel, Dr. M. M. Development and Vali-dation of stability indicating chromatographic method for simultaneous estimation of cilnidipine and irbesartan in pharmaceutical dosage form. WJPR, 2019, 7(8), 1124-1135.
[77]
Gandla, K.; Rao, JS.; Kumar, JR. New stability indicating validated RP-HPLC method for simultaneous estimation of irbesartan and atrovastatin in combined tablet dosage forms Ame.J.pharm.Tech.res, 2015, 5(4), 380-390.
[78]
Prashanthi, R.; Raghavi, K.; Sindhura, M.; Anupama, B.; Nal-luri, B.N. Development and validation of a sensitive RP-HPLC-PDA method for assay of Irbesartan in pure and phar-maceutical dosage forms. Int. J. Pharma Bio Sci., 2012, 3, 397-406.
[79]
Coudore, F.; Harvard, L.; Lefeuvre, S.; Billaud, E.M.; Beaune, P.; Bobrie, G.; Azizi, M.; Prognon, P.; Laurent, S. HPLC–DAD Analysis of hydrochlorothiazide and irbesartan in hyperten-sive patients on fixed-dose combination therapy. Chromatographia, 2011, 74(7-8), 559.
[http://dx.doi.org/10.1007/s10337-011-2111-6]
[80]
Rao, K.T.; Rao, L.V. Rapid Stability-indicating RRLC Method for simultaneous estimation of irbesartan and its related impurities. Indian J. Pharm. Sci., 2016, 78(2), 252-258.
[http://dx.doi.org/10.4172/pharmaceutical-sciences.1000110]
[81]
Golubović, J.; Protić, A.; Otašević, B.; Zečević, M. Quantitative structure-retention relationships applied to development of liquid chromatography gradient-elution method for the separation of sartans. Talanta, 2016, 150, 190-197.
[http://dx.doi.org/10.1016/j.talanta.2015.12.035] [PMID: 26838399]
[82]
González, L.; López, J.A.; Alonso, R.M.; Jiménez, R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. A, 2002, 949(1-2), 49-60.
[http://dx.doi.org/10.1016/S0021-9673(01)01496-0] [PMID: 11999756]
[83]
Khodke, A.S.; Potale, L.V.; Damle, M.C.; Bothara, K.G. A validated stability indicating HPTLC method for simultaneous estimation of irbesartan and hydrochlorothiazide. Pharm. Methods, 2010, 1(1), 39-43.
[http://dx.doi.org/10.1016/S2229-4708(10)11005-X] [PMID: 23781414]
[84]
Salah, G.A.; Abd El-Wadood, H.M.; Khairy, M.; Khorshed, A.A. Two selective HPTLC methods for determination of some angiotensin II receptor antagonists in tablets and biological fluids. Biomed. Chromatogr., 2017, 31(7)e3916
[http://dx.doi.org/10.1002/bmc.3916] [PMID: 27943353]
[85]
El-Shaboury, S.R.; Hussein, S.A.; Mohamed, N.A.; El-Sutohy, M.M. Stability-indicating densitometric determination of some angiotensin II receptor antagonists in presence of their degradation products. Acta Chromatogr., 2013, 25(1), 79-95.
[http://dx.doi.org/10.1556/AChrom.25.2013.1.4]
[86]
Lakshmi sivasubramanian.; KS Lakshmi. Simultaneous esti-mation of irbesartan, telmisartan, hydrochlorothiazide and ramipril in combined dosage forms by validated HPTLC Method. J AnalPharm Res., 2017, 4(4), 00112.
[87]
Rosangluaia, S.P.; Malarkodi, V. Validated HPTLC method for simultaneous estimation of irbesartan and hydrochlorthiazide in a tablet dosage form. Pharma Chem., 2011, 3(5), 310-317.
[88]
Hussein, S.; Abd El-Wadood, H.; Abou-Elwafa Abdallah, M.; Khorshed, A. Application of high-performance thin-layer chromatography for screening and simultaneous determination of some angiotensin II receptor antagonists in dosage forms and plasma. J. Planar Chromatogr. Mod. TLC, 2014, 27(3), 192-198.
[http://dx.doi.org/10.1556/JPC.27.2014.3.8]
[89]
Shah, D.A.; Patel, D.V.; Mehta, F.A.; Chhalotiya, U.K.; Bhatt, K.K. High-performance thin-layer chromatography method for estimating the stability of a combination of irbesartan and amlodipine besylate. Journal of Taibah University for Science, 2015, 9(2), 177-186.
[http://dx.doi.org/10.1016/j.jtusci.2014.07.007]
[90]
Lee, H.W.; Ji, H.Y.; Park, E.S.; Lee, K.C.; Lee, H.S. Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan. J. Sep. Sci., 2009, 32(14), 2353-2358.
[http://dx.doi.org/10.1002/jssc.200900148] [PMID: 19536783]
[91]
Ferreirós, N.; Dresen, S.; Alonso, R.M.; Weinmann, W. Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. Ther. Drug Monit., 2007, 29(6), 824-834.
[http://dx.doi.org/10.1097/FTD.0b013e31815d0f66] [PMID: 18043483]
[92]
Wani, T.A.; Zargar, S. New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. Yao Wu Shi Pin Fen Xi, 2015, 23(3), 569-576.
[http://dx.doi.org/10.1016/j.jfda.2015.02.008] [PMID: 28911717]
[93]
Qiu, X.; Wang, Z.; Wang, B.; Zhan, H.; Pan, X.; Xu, R.A. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2014, 957, 110-115.
[http://dx.doi.org/10.1016/j.jchromb.2014.03.002] [PMID: 24681823]
[94]
Shah, R.P.; Sahu, A.; Singh, S. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR. J. Pharm. Biomed. Anal., 2010, 51(5), 1037-1046.
[http://dx.doi.org/10.1016/j.jpba.2009.11.008] [PMID: 20018473]
[95]
Katteboina, M.Y.; Pilli, N.R.; Inamadugu, J.K. Satla, SR. LC-MS/MS assay for irbesartan in human plasma using solid phase extraction technique:a pharmacokinetic study. Int. J. Pharm. Pharm. Sci., 2015, 7(9), 335-340.
[96]
Tutunji, L.F.; Tutunji, M.F.; Alzoubi, M.I.; Khabbas, M.H.; Arida, A.I. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies. J. Pharm. Biomed. Anal., 2010, 51(4), 985-990.
[http://dx.doi.org/10.1016/j.jpba.2009.10.023] [PMID: 20004542]
[97]
Tiwari, HK.; Monif, T.; Verma, PR.; Reyar, S.; Khuroo, AH.; Mishra, S. Quantitative estimation of irbesartan in two different matrices and its application to human and dog bioavailability studies using LC-MS/MS. Asian J. Pharm. Sci., 2013, 8(6), 346-355.
[98]
Prasad, S.V.; Shivakumar, S.; Sudhir, T.; Mital, R. Rao, GD. LC/MS/MS method for the simultaneous estimation of losar-tan potassium and irbesartan in rat plasma. Int. J. Pharm. Pharm. Sci., 2009, 1, 206-215.
[99]
Jain, P. Yashumati, R.; Bhardwaj, Dharma Kishore. A liquid chromatography tandem mass spectrometry based method for the simultaneous determination of irbesartan and hydrochlorothiazide in human plasma. Int. J. Drug Dev. & Res., 2014, 6(3), 18-31.
[100]
Lu, C.Y.; Feng, C.H. Quantitation of irbesartan and major proteins in human plasma by mass spectrometry with time-of-flight analyzer. J. Pharm. Biomed. Anal., 2011, 54(1), 100-105.
[http://dx.doi.org/10.1016/j.jpba.2010.07.019] [PMID: 20724092]
[101]
Ganesan, M.; Nanjundan, S.; Gomathi, M.; Muralidharan, S. Method development and validation of Irbesartan using LCMS/MS: Application to pharmacokinetic studies. J. Chem. Pharm. Res., 2010, 2(4), 740-746.
[102]
Bozal, B.; Doğan-Topal, B.; Uslu, B.; Ozkan, S.A.; Aboul-Enein, H.Y. Quantitative analysis of irbesartan in pharmaceu-ticals and human biological fluids by voltammetry. Anal. Lett., 2009, 42(14), 2322-2338.
[http://dx.doi.org/10.1080/00032710903137491]
[103]
Gupta, V.K.; Jain, R.; Agarwal, S.; Mishra, R.; Dwivedi, A. Electrochemical determination of antihypertensive drug irbesartan in pharmaceuticals. Anal. Biochem., 2011, 410(2), 266-271.
[http://dx.doi.org/10.1016/j.ab.2010.11.024] [PMID: 21094117]
[104]
Hillaert, S.; Van den Bossche, W. Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J. Pharm. Biomed. Anal., 2003, 31(2), 329-339.
[http://dx.doi.org/10.1016/S0731-7085(02)00643-X] [PMID: 12609672]
[105]
Sema Koyuturk. Simultaneous determination of irbesartan and hydrochlorothiazide in tablets by CE-DAD. J. Biol. Chem., 2015, 43(3), 145-152.

Rights & Permissions Print Cite
Article Metrics
17
© 2024 Bentham Science Publishers | Privacy Policy